Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

Eric S. Christenson, Theodore James, Vineet Agrawal, Ben H. Park

Research output: Contribution to journalArticle

Abstract

Objectives: To review the evidence for the use of various biomarkers in the detection of chemotherapy associated cardiac damage. Design and methods: Pubmed.gov was queried using the search words chemotherapy and cardiac biomarkers with the filters of past 10. years, humans, and English language. An emphasis was placed on obtaining primary research articles looking at the utility of biomarkers for the detection of chemotherapy-mediated cardiac injury. Results: Biomarkers may help identify patients undergoing treatment who are at high risk for cardiotoxicity and may assist in identification of a low risk cohort that does not necessitate continued intensive screening. cTn assays are the best studied biomarkers in this context and may represent a promising and potentially valuable modality for detecting cardiac toxicity in patients undergoing chemotherapy. Monitoring cTnI levels may provide information regarding the development of cardiac toxicity before left ventricular dysfunction becomes apparent on echocardiography or via clinical symptoms. A host of other biomarkers have been evaluated for their utility in the field of chemotherapy related cardiac toxicity with intermittent success; further trials are necessary to determine what role they may end up playing for prediction and prognostication in this setting. Conclusions: Biomarkers represent an exciting potential complement or replacement for echocardiographic monitoring of chemotherapy related cardiac toxicity which may allow for earlier realization of the degree of cardiac damage occurring during treatment, creating the opportunity for more timely modulation of therapy.

Original languageEnglish (US)
Pages (from-to)223-235
Number of pages13
JournalClinical Biochemistry
Volume48
Issue number4-5
DOIs
StatePublished - Mar 1 2015

Fingerprint

Chemotherapy
Biomarkers
Toxicity
Drug Therapy
Patient treatment
Echocardiography
Monitoring
Left Ventricular Dysfunction
Cardiotoxicity
PubMed
Assays
Screening
Language
Therapeutics
Modulation
Wounds and Injuries
Research

Keywords

  • Anthracyclines
  • Cardiac toxicity
  • Chemotherapy
  • Natriuretic peptides
  • Troponin

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. / Christenson, Eric S.; James, Theodore; Agrawal, Vineet; Park, Ben H.

In: Clinical Biochemistry, Vol. 48, No. 4-5, 01.03.2015, p. 223-235.

Research output: Contribution to journalArticle

Christenson, Eric S. ; James, Theodore ; Agrawal, Vineet ; Park, Ben H. / Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. In: Clinical Biochemistry. 2015 ; Vol. 48, No. 4-5. pp. 223-235.
@article{e63be08dfea04016ac9a0fe905cbb594,
title = "Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity",
abstract = "Objectives: To review the evidence for the use of various biomarkers in the detection of chemotherapy associated cardiac damage. Design and methods: Pubmed.gov was queried using the search words chemotherapy and cardiac biomarkers with the filters of past 10. years, humans, and English language. An emphasis was placed on obtaining primary research articles looking at the utility of biomarkers for the detection of chemotherapy-mediated cardiac injury. Results: Biomarkers may help identify patients undergoing treatment who are at high risk for cardiotoxicity and may assist in identification of a low risk cohort that does not necessitate continued intensive screening. cTn assays are the best studied biomarkers in this context and may represent a promising and potentially valuable modality for detecting cardiac toxicity in patients undergoing chemotherapy. Monitoring cTnI levels may provide information regarding the development of cardiac toxicity before left ventricular dysfunction becomes apparent on echocardiography or via clinical symptoms. A host of other biomarkers have been evaluated for their utility in the field of chemotherapy related cardiac toxicity with intermittent success; further trials are necessary to determine what role they may end up playing for prediction and prognostication in this setting. Conclusions: Biomarkers represent an exciting potential complement or replacement for echocardiographic monitoring of chemotherapy related cardiac toxicity which may allow for earlier realization of the degree of cardiac damage occurring during treatment, creating the opportunity for more timely modulation of therapy.",
keywords = "Anthracyclines, Cardiac toxicity, Chemotherapy, Natriuretic peptides, Troponin",
author = "Christenson, {Eric S.} and Theodore James and Vineet Agrawal and Park, {Ben H.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.clinbiochem.2014.10.013",
language = "English (US)",
volume = "48",
pages = "223--235",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "4-5",

}

TY - JOUR

T1 - Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

AU - Christenson, Eric S.

AU - James, Theodore

AU - Agrawal, Vineet

AU - Park, Ben H.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Objectives: To review the evidence for the use of various biomarkers in the detection of chemotherapy associated cardiac damage. Design and methods: Pubmed.gov was queried using the search words chemotherapy and cardiac biomarkers with the filters of past 10. years, humans, and English language. An emphasis was placed on obtaining primary research articles looking at the utility of biomarkers for the detection of chemotherapy-mediated cardiac injury. Results: Biomarkers may help identify patients undergoing treatment who are at high risk for cardiotoxicity and may assist in identification of a low risk cohort that does not necessitate continued intensive screening. cTn assays are the best studied biomarkers in this context and may represent a promising and potentially valuable modality for detecting cardiac toxicity in patients undergoing chemotherapy. Monitoring cTnI levels may provide information regarding the development of cardiac toxicity before left ventricular dysfunction becomes apparent on echocardiography or via clinical symptoms. A host of other biomarkers have been evaluated for their utility in the field of chemotherapy related cardiac toxicity with intermittent success; further trials are necessary to determine what role they may end up playing for prediction and prognostication in this setting. Conclusions: Biomarkers represent an exciting potential complement or replacement for echocardiographic monitoring of chemotherapy related cardiac toxicity which may allow for earlier realization of the degree of cardiac damage occurring during treatment, creating the opportunity for more timely modulation of therapy.

AB - Objectives: To review the evidence for the use of various biomarkers in the detection of chemotherapy associated cardiac damage. Design and methods: Pubmed.gov was queried using the search words chemotherapy and cardiac biomarkers with the filters of past 10. years, humans, and English language. An emphasis was placed on obtaining primary research articles looking at the utility of biomarkers for the detection of chemotherapy-mediated cardiac injury. Results: Biomarkers may help identify patients undergoing treatment who are at high risk for cardiotoxicity and may assist in identification of a low risk cohort that does not necessitate continued intensive screening. cTn assays are the best studied biomarkers in this context and may represent a promising and potentially valuable modality for detecting cardiac toxicity in patients undergoing chemotherapy. Monitoring cTnI levels may provide information regarding the development of cardiac toxicity before left ventricular dysfunction becomes apparent on echocardiography or via clinical symptoms. A host of other biomarkers have been evaluated for their utility in the field of chemotherapy related cardiac toxicity with intermittent success; further trials are necessary to determine what role they may end up playing for prediction and prognostication in this setting. Conclusions: Biomarkers represent an exciting potential complement or replacement for echocardiographic monitoring of chemotherapy related cardiac toxicity which may allow for earlier realization of the degree of cardiac damage occurring during treatment, creating the opportunity for more timely modulation of therapy.

KW - Anthracyclines

KW - Cardiac toxicity

KW - Chemotherapy

KW - Natriuretic peptides

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=84924455468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924455468&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2014.10.013

DO - 10.1016/j.clinbiochem.2014.10.013

M3 - Article

C2 - 25445234

AN - SCOPUS:84924455468

VL - 48

SP - 223

EP - 235

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 4-5

ER -